Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158408 | 0.92 | MEN1 (0.54) | NPC1RAB9AMEN1KMT2AACHE | |
| Hydrochloric Acid SCHEMBL3104691 | 0.91 | MEN1 (0.52) | NPC1RAB9AMEN1KMT2AACHE | |
| SCHEMBL13158406 | 0.89 | NPC1 (0.47) | NPC1RAB9AACHEKCNH2KDM4E | |
| Hydrochloric Acid SCHEMBL3105077 | 0.88 | NPC1 (0.49) | NPC1RAB9AACHEKCNH2KDM4E | |
| Hydrochloric Acid SCHEMBL28426184 | 0.79 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2AACHE | |
| SCHEMBL3096733 | 0.79 | KMT2A (0.49) | MEN1KMT2AACHEKCNH2KDM4E | |
| SCHEMBL2299320 | 0.77 | MEN1 (0.52) | NPC1RAB9AMEN1KMT2AKCNH2 | |
| SCHEMBL3658790 | 0.76 | MEN1 (0.52) | NPC1RAB9AMEN1KMT2AHPGDS | |
| SCHEMBL13993235 | 0.76 | ACHE (0.45) | NPC1RAB9AACHEPTGDR2KDM4E | |
| Bromide SCHEMBL2980010 | 0.76 | MEN1 (0.51) | NPC1RAB9AMEN1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| CN-101454299-A | Ureide derivative and use thereof for medical purposes | TORAY INDUSTRIES (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | NPC1 1768/4885RAB9A 2013/4885MEN1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.